In addition, the soluble IL-6 receptor is expressed at higher levels in many ER+ breast cancers as compared to the triple negative subtype4, enabling IL-6 to impact intracellular signaling through the JAK/STAT pathway. This evidence concerns the gene SOAT1 and breast cancer.